Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens-Reference-Cited by-同舟云学术

Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens

Published:2012-07-09 Issue:1 Volume:10 Page:
ISSN:1479-5876
Container-title:Journal of Translational Medicine
language:en
Short-container-title:J Transl Med

Author:

Kono Koji,Iinuma Hisae,Akutsu Yasunori,Tanaka Hiroaki,Hayashi Naoko,Uchikado Yasuto,Noguchi Tsuyoshi,Fujii Hideki,Okinaka Kota,Fukushima Ryoji,Matsubara Hisahiro,Ohira Masaichi,Baba Hideo,Natsugoe Shoji,Kitano Seigou,Takeda Kazuyoshi,Yoshida Koji,Tsunoda Takuya,Nakamura Yusuke

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/1479-5876-10-141.pdf

Reference26 articles.

1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF: Impact study investigators. Sipuleucel-t immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010, 363: 411-422. 10.1056/NEJMoa1001294.

2. Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M: Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008, 26: 5950-5956. 10.1200/JCO.2008.16.1927.

3. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J: gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011, 364: 2119-2127. 10.1056/NEJMoa1012863.

4. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP: Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011, 29: 2787-2794. 10.1200/JCO.2010.33.3005.

5. Cecco S, Muraro E, Giacomin E, Martorelli D, Lazzarini R, Baldo P: Cancer vaccines in phase II/III clinical trials: state of the art and future perspectives. Curr Cancer Drug Targets. 2011, 11: 85-102. 10.2174/156800911793743664.

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multi-omics analysis of overexpressed tumor-associated proteins: gene expression, immunopeptide presentation, and antibody response in oropharyngeal squamous cell carcinoma, with a focus on cancer-testis antigens;Frontiers in Immunology;2024-07-29

2. Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis;Journal of Clinical Oncology;2024-07-20

3. A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma;Esophagus;2024-07-11

4. Birinapant Reshapes the Tumor Immunopeptidome and Enhances Antigen Presentation;International Journal of Molecular Sciences;2024-03-25

5. Randomized phase I/II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma;Hepatology Research;2023-12-27